CoChat

Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells

Open access
Oh, Yumin, Park, Ogyi, Swierczewska, Magdalena, Hamilton, James P., Park, Jong‐Sung, Kim, Tae Hyung, Lim, Sung‐Mook, Eom, Hana, Jo, Dong Gyu, Lee, Choong‐Eun, Kechrid, Raouf, Mastorakos, Panagiotis, Zhang, Clark, Hahn, Sei Kwang, Jeon, Ok‐Cheol, Byun, Youngro, Kim, Kwangmeyung, Hanes, Justin, Lee, Kang Choon, Pomper, Martin G., Gao, Bin, Lee, Seulki · 2016 · Hepatology
Cited by 77

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Liver fibrosis is a common outcome of chronic liver disease that leads to liver cirrhosis and hepatocellular carcinoma. No US Food and Drug Administration–approved targeted antifibrotic therapy exists. Activated hepatic stellate cells (aHSCs) are the major cell types responsible for liver fibrosis; therefore, eradication of aHSCs, while preserving quiescent HSCs and other normal cells, is a logical strategy to stop and/or reverse liver fibrogenesis/fibrosis. However, there are no effective approaches to specifically deplete aHSCs during fibrosis without systemic toxicity. aHSCs are associated with elevated expression of death receptors and become sensitive to tumor necrosis factor–related apoptosis‐inducing ligand (TRAIL)‐induced cell death. Treatment with recombinant TRAIL could be a potential strategy to ameliorate liver fibrosis; however, the therapeutic application of recombinant TRAIL is halted due to its very short half‐life. To overcome this problem, we previously generated PEGylated TRAIL (TRAIL PEG) that has a much longer half‐life in rodents than native‐type TRAIL. In this study, we demonstrate that intravenous TRAIL PEG has a markedly extended half‐life over native‐type TRAIL in nonhuman primates and has no toxicity in primary human hepatocytes. Intravenous injection of TRAIL PEG directly induces apoptosis of aHSCs in vivo and ameliorates carbon tetrachloride‐induced fibrosis/cirrhosis in rats by simultaneously down‐regulating multiple key fibrotic markers that are associated with aHSCs.Conclusion: TRAIL‐based therapies could serve as new therapeutics for liver fibrosis/cirrhosis and possibly other fibrotic diseases. (H epatology 2016;64:209–223)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.28432

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 77

Metadata

Authors
Oh, Y., Park, O., Swierczewska, M., Hamilton, J. P., Park, J., Kim, T. H., Lim, S., Eom, H., Jo, D. G., Lee, C., Kechrid, R., Mastorakos, P., Zhang, C., Hahn, S. K., Jeon, O., Byun, Y., Kim, K., Hanes, J., Lee, K. C., Pomper, M. G., Gao, B., & Lee, S.
Venue
Hepatology
Published
2016-03-03
Volume
64
Issue
1
Pages
209-223
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2256403975
Cited by
77
References
9
FWCI
2.90
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells. https://app.cochat.ai/papers/10.1002/hep.28432
The paper
Oh, Y., Park, O., Swierczewska, M., Hamilton, J. P., Park, J., Kim, T. H., Lim, S., Eom, H., Jo, D. G., Lee, C., Kechrid, R., Mastorakos, P., Zhang, C., Hahn, S. K., Jeon, O., Byun, Y., Kim, K., Hanes, J., Lee, K. C., . . . Lee, S. (2016). Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells. Hepatology. https://doi.org/10.1002/hep.28432

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.